With the European Union promoting a Better Regulation and REFIT agenda, the Call for Evidence and the need for jobs and economic growth, the financial sector may be forgiven for having entertained the notion that the regulatory rhythm would slow down.
Leaving the EU, joining the WTO and negotiating new FTAs amounts to a dizzying volume of negotiations for the UK across several fronts – London, Brussels, Geneva and, let’s say, Washington, New Delhi and Sydney amongst others – all within an extremely limited timeframe of two years or so.
In the aftermath of Britain’s decision to leave the European Union, the only thing that can be said with any certainty is that the country faces a sustained period of uncertainty.
Brexit, in all foreseeable scenarios, will mean a departure from the EU’s Common Agricultural Policy (CAP) subsidy and regulatory regime – a stark reality for the agriculture sector.
The economic and political upheaval since the referendum result to leave the EU have been felt deeply in the life science sector. The immediate impact on big Pharma share prices was not negative – a little safe stock haven – but the long term outlook for the industry in the UK is bleak.
Europe’s healthcare sector benefits greatly from the single market. Few medicines, diagnostics or medical devices are manufactured or licensed solely in the Member State where they are administered.